Having trouble accessing articles? Reset your cache.

A view of immune reprogramming from ASH

ASH abstracts reveal new mechanisms and consequences of immune cell repolarization in hematology

ASH presentations on immune reprogramming point to new targets and mechanisms that control macrophage and T cell phenotype switching, and highlight the phenomenon's translational relevance in diseases beyond solid tumors.

Strategies to convert immunosuppressive macrophage and T cell subsets into proinflammatory cells are gaining momentum as a way to simultaneously release the brakes and rev up the gas for antitumor immunity (see "Flipping the Switch in Immuno-oncology").

The approach has primarily been framed as a way to reprogram the microenvironment in solid tumors, but abstracts released ahead of the 2019 meeting of the American Society of Hematology (ASH) shine a light on immune polarization in hematological cancers and other blood disorders.

Presentations from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) and others suggest macrophage and T cell reprogramming contribute to therapeutic responses to inhibitors

Read the full word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE